Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MEM 3454: Phase IIa started

Memory began a double-blind, placebo-controlled Phase IIa trial in about 160 patients

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE